Generation Bio Co. (NASDAQ:GBIO) Director Anthony G. Quinn Purchases 125,791 Shares

Generation Bio Co. (NASDAQ:GBIO - Get Free Report) Director Anthony G. Quinn acquired 125,791 shares of the firm's stock in a transaction that occurred on Friday, January 10th. The stock was purchased at an average cost of $0.96 per share, for a total transaction of $120,759.36. Following the completion of the purchase, the director now directly owns 214,286 shares of the company's stock, valued at $205,714.56. The trade was a 142.14 % increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

Generation Bio Stock Down 4.3 %

Generation Bio stock traded down $0.04 during trading hours on Tuesday, hitting $0.88. The stock had a trading volume of 1,241,984 shares, compared to its average volume of 728,243. The business's 50 day simple moving average is $1.35 and its 200-day simple moving average is $2.13. Generation Bio Co. has a one year low of $0.75 and a one year high of $4.65. The stock has a market cap of $58.78 million, a price-to-earnings ratio of -0.40 and a beta of 2.72.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the business. Bank of New York Mellon Corp lifted its holdings in Generation Bio by 31.2% during the 2nd quarter. Bank of New York Mellon Corp now owns 186,756 shares of the company's stock worth $527,000 after buying an additional 44,378 shares during the period. Rhumbline Advisers lifted its stake in shares of Generation Bio by 7.4% in the second quarter. Rhumbline Advisers now owns 78,903 shares of the company's stock worth $222,000 after acquiring an additional 5,430 shares during the period. American Century Companies Inc. lifted its stake in shares of Generation Bio by 199.3% in the second quarter. American Century Companies Inc. now owns 31,786 shares of the company's stock worth $90,000 after acquiring an additional 21,167 shares during the period. Cubist Systematic Strategies LLC boosted its holdings in Generation Bio by 91.0% in the second quarter. Cubist Systematic Strategies LLC now owns 19,046 shares of the company's stock valued at $54,000 after acquiring an additional 9,075 shares during the last quarter. Finally, The Manufacturers Life Insurance Company increased its position in Generation Bio by 8.7% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 164,573 shares of the company's stock valued at $464,000 after purchasing an additional 13,104 shares during the period. Institutional investors own 95.22% of the company's stock.

Analyst Ratings Changes

A number of research firms have issued reports on GBIO. Needham & Company LLC decreased their target price on Generation Bio from $10.00 to $8.00 and set a "buy" rating on the stock in a research report on Wednesday, January 8th. Wedbush reaffirmed an "outperform" rating and set a $5.00 target price on shares of Generation Bio in a research note on Thursday, November 7th.

About Generation Bio

Generation Bio Co develops non-viral genetic medicines for the treatment of rare and prevalent diseases. The company develops cell-targeted lipid nanoparticle (ctLNP) platform, a modular delivery system for nucleic acids to avoid off-target clearance by the liver and spleen that enables ctLNPs to persist in systemic circulation, which allows for highly selective and potent ligand-driven targeting to specific tissues and cell types; and novel immune-quiet DNA (iqDNA) to enable long-lasting high levels of gene expression from non-integrating episomes and avoids innate immune sensors that have long prevented DNA from use in non-viral systems.